KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Quoc-Dien Trinh, Daniel J George, Neal Shore, Egils Vjaters, David Olmos, Andrea Juliana P de Santana Gomes, Augusto Cesar de Andrade Mota, Natasha Littleton, Shankar Srinivasan, Frank Verholen, Kunhi Parambath Haresh, Fred Saad

Prostate Cancer Prostatic Dis 10.1038/s41391-026-01131-6

PMID42323390
PMCID-
DOI10.1038/s41391-026-01131-6
发表日期2026-06-20
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: This analysis reports efficacy and safety data in the subgroup of Black patients from the ARANOTE phase 3 trial. METHODS: Patients starting on androgen-deprivation therapy (ADT) were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo. Of the total ARANOTE population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were Black. RESULTS: In Black patients, darolutamide + ADT improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% vs ADT alone, consistent with the overall population. CONCLUSIONS: In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。